AstraZeneca ( AZN) announced that it submitted a supplemental new drug application to use its Atacand hypertension treatment to treat chronic heart failure. The company's NDA includes data from the CHARM clinical trials, a comprehensive study of the effect that angiotensin receptor blockers like Atacand have on heart failure in patients. Under three independent, double-blind studies of more than 7,600 patients, Atacand was shown to reduce cardiovascular deaths by 16% when compared to a placebo. The company's application to use Atacand to treat heart failure as well as high blood pressure was expected. The results of the CHARM trials were released in September of last year. Shares of AstraZeneca failed to catch a bid on Thursday's broad market decline, with shares dropping 56 cents, or 1.2%, to $45.08.